Miglitol and hepatotoxicity in type 2 diabetes mellitus.
R F
RF
Carlson
D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives; D020909:Acarbose / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000201:enzymology; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005944:Glucosamine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D050112:Imino Pyranoses; D008099:Liver / Q000187:drug effects* / Q000201:enzymology*; D008111:Liver Function Tests; D000637:Transaminases / Q000097:blood*
D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D050112:Imino Pyranoses; C045621:miglitol; D017485:1-Deoxynojirimycin; D000637:Transaminases; D005944:Glucosamine; D020909:Acarbose